Introduction {#section5-1470320317752955}
============

Diabetic retinopathy (DR) is one of the most devastating microvascular complications of diabetes mellitus^[@bibr1-1470320317752955]^ and remains a major cause of visual morbidity in developed and developing countries.^[@bibr2-1470320317752955],[@bibr3-1470320317752955]^ Epidemiological studies have shown that DR exists in almost all individuals with long-standing type 1 diabetes mellitus (T1DM), and approximately 60% of patients with type 2 diabetes mellitus (T2DM) develop retinopathy.^[@bibr4-1470320317752955]^ In addition to the increased classic cardiovascular risk factors in diabetes, genetic factors may contribute to the development of these complications. Indeed, monozygotic twins with T2DM show a substantial concordance for the development of DR, suggesting that genetic factors may have a role in DR.^[@bibr5-1470320317752955]^ Several genetic markers have been studied,^[@bibr6-1470320317752955][@bibr7-1470320317752955][@bibr8-1470320317752955][@bibr9-1470320317752955]--[@bibr10-1470320317752955]^ but up to now, no main genetic locus has been identified.

The renin-angiotensin system (RAS) consists of renin, angiotensinogen (AGT), angiotensin-converting enzyme (ACE), ACE2, angiotensin II type 1 receptor (AT1R) and AT2R.^[@bibr11-1470320317752955]^ In human physiology, RAS is fundamental to blood pressure regulation; as such, each component is potentially involved in the etiology of the polygenic disorder known as primary hypertension.^[@bibr12-1470320317752955]^ AGT is converted to angiotensin I by renin, and subsequently into angiotensin II by ACE.^[@bibr13-1470320317752955]^ ACE plays an important role in the regulation of systemic and renal vascular circulation by converting angiotensin I into vasoconstrictor molecule angiotensin II.^[@bibr14-1470320317752955]^ Higher levels of renin activity and ACE activity during the course of diabetes result in an excess of angiotensin II in the eye, abnormally constricted retinal arterioles, elevated local intravascular blood pressure, reduced retinal blood flow, increased permeability of retinal blood vessels, and ocular neovascularization.^[@bibr15-1470320317752955]^ Interestingly, the *ACE* gene intron 16 insertion/deletion (I/D) polymorphism accounts for about one-half of the phenotypic variance in plasma ACE levels.^[@bibr16-1470320317752955]^

In recent years, several groups of researchers have focused on the relationship between RAS and DR.^[@bibr17-1470320317752955][@bibr18-1470320317752955]--[@bibr19-1470320317752955]^ However, their findings are inconsistent. Recently, we have shown an association of diabetic glomerulosclerosis with immunoreactivity of *ACE* and *AGT*.^[@bibr20-1470320317752955]^ Here we report that the *ACE* and *AGT* gene polymorphisms might not have a significant effect on DR in a group of Chinese T2DM patients.

Participants, materials and methods {#section6-1470320317752955}
===================================

Participants and clinical measurements {#section7-1470320317752955}
--------------------------------------

In this cross-sectional clinical-genetic association study, we consecutively recruited 1491 T2DM patients. Among them, 345 had been diagnosed as DR and 1146 were diagnosed as diabetic non-retinopathy (DNR). Cases clinically diagnosed and sampled from the database of the university-affiliated hospital before 2012 participated in this study. Patients with a controlled diet and the use of antihypertensive drugs and RAS blocking were excluded. Before taking blood samples, we informed each patient about the aim of the study and a written consent in accordance with the guidelines of the institutional review board of the Guilin Medical University was given. This study was approved by the ethical committee of Guilin Medical University (GLMC191211HL). All cases were initially diagnosed with T2DM by a qualified endocrinologist. DM was diagnosed and classified according to 1985 World Health Organization (WHO) criteria. Patients underwent detailed eye examination with ophthalmoscopy, funduscopy and fundus photography to assess DR. All patients underwent complete physical examination including body mass index (BMI), fasting plasma glucose (FPG), glycated hemoglobin (HbA~1c~), lipid profile (triglyceride (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C)), albumin-to-creatinine ratio (ACR) and albumin excretion rate (AER) according the previous report.^[@bibr20-1470320317752955]^

*ACE* and *AGT* genotyping {#section8-1470320317752955}
--------------------------

Genomic DNA of patients was extracted using protocols reported in our previous article.^[@bibr21-1470320317752955]^ Polymerase chain reaction (PCR) was used to determine the *ACE* gene I/D and *AGT* gene methionine (M)/threonine T polymorphisms through primers flanking the polymorphic region of intron 16 and 354 bp of exon 2, respectively. The primers used in this study were 5′-CTGGAGACCACTCCCATCCTTTCT-3′ and 5′-GATGTGGCCATCACATTCGTCAGAT-3′ for *ACE* I/D, and were 5′-CAGGGTGCTGTCCACACTGGACCCC-3′ and 5′-CCGTTTGTGCAGGGCCTGGCTCTCT-3′ for *AGT* M/T gene polymorphism, respectively.^[@bibr20-1470320317752955]^ PCR amplification revealed a 190 bp fragment (*ACE* D allele) and/or a 490 bp fragment (*ACE* I allele), and a 266 bp fragment (*AGT* M235 allele) and/or a 303 bp fragment (*AGT* 235T allele). Genotyping for the *ACE* gene I/D and *AGT* gene M/T polymorphism followed the methods described in our recent publication.^[@bibr20-1470320317752955]^

Definitions and calculations {#section9-1470320317752955}
----------------------------

Visual acuity was assessed systematically by specialist ophthalmologists who determined the presence and graded the severity of DR according to the Early Treatment of Diabetic Retinopathy Study (ETDRS) scale.^[@bibr22-1470320317752955]^ DR patients included nonproliferative and proliferative DR, and DM patients without retinopathy were defined as controls. Hypertension was defined as an average blood pressure ≥ 140/90 mm Hg on at least three different occasions at rest state or by the presence of antihypertensive treatment.^[@bibr20-1470320317752955]^ Renal status was defined by AER and ACR: normoalbuminuria (AER \< 20 μg/min or ACR \< 30 mg/g), microalbuminuria (20 ≤ AER \< 200 μg/min or 30 ≤ ACR \< 300 mg/g), macroalbuminuria (AER ≥ 200 μg/min or ACR ≥ 300 mg/g).^[@bibr20-1470320317752955]^ BMI was derived according to the following formula: BMI = body weight (in kilograms)/square of the height (in meters).^[@bibr23-1470320317752955],[@bibr24-1470320317752955]^ According to the BMI value, patients were divided into an obesity group (BMI ≥ 25 kg/m^2^), an overweight group (23 kg/m^2^ ≤ BMI \< 25 kg/m^2^), a normal group (18.5 kg/m^2^ ≤ BMI \< 23 kg/m^2^) and a lean group (BMI \< 18.5 kg/m^2^); because of the small sample size of overweight and lean patients, we explored the distribution of genotypes and alleles only in obese and normal patients.

Statistical analysis {#section10-1470320317752955}
--------------------

The data in this study were expressed as mean ± standard deviation (SD), median (interquartile range) or percentage, as appropriate. If the alleles were in Hardy-Weinberg equilibrium, the χ^2^ test was performed to compare the genotype distribution of each polymorphism. For categorical variables, χ^2^ tests were used to find out differences between groups. Differences in continuous variables were analyzed by Student's *t*-test and one-way analysis of covariance in normal distribution, and Mann--Whitney *U* test was performed for abnormal distribution. To assess the association of disease with genotype, we used binary logistic regression analysis after adjusting for various factors. The *p* value \< 0.05 was defined as statistically significant. Post-hoc power calculation was conducted by using the PS software (Power and Sample Size Calculation).^[@bibr25-1470320317752955][@bibr26-1470320317752955]--[@bibr27-1470320317752955]^ Statistical analyses were performed using the SPSS program (SPSS version 15, SPSS Inc, Chicago, IL, USA).

Results {#section11-1470320317752955}
=======

Characteristics of patient samples and clinical findings {#section12-1470320317752955}
--------------------------------------------------------

In this study, a total of 1491 patients with T2DM were enrolled: 345 individuals with DR and 1146 diabetic patients without retinopathy. Successful genotyping for the *ACE* I/D and *AGT* M/T gene polymorphisms were obtained from 1485 patients (344 DR cases) and 1245 (293 DR cases) participants, respectively. The demographic characteristics of T2DM patients with DR are displayed in [Table 1](#table1-1470320317752955){ref-type="table"}. Compared with DNR patients, the DR cases were older (*p* \< 0.001) and had a longer duration of known diabetes (*p* \< 0.001), a higher proportion of hypertension (*p* \< 0.001), higher levels of HbA~1c~ (*p* \< 0.001), FPG (*p* \< 0.001), TC (*p* \< 0.001), TG (*p* = 0.002), plasma urea (*p* \< 0.001), plasma creatinine (*p* \< 0.001), ACR (*p* \< 0.001), AER (*p* = 0.011), BMI (*p* = 0.009), systolic blood pressure (SBP, *p* \< 0.001) and diastolic blood pressure (DBP, *p* \< 0.001).

###### 

Clinical characteristic of 1491 patients and concordance between DR and diabetic nephropathy.

![](10.1177_1470320317752955-table1)

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                        Total                DR                     DNR                  *p*
  ----------------------------------------------------- -------------------- ---------------------- -------------------- ----------------------------------------------------------------
  ***n***                                               1491                 345                    1146                 --

  **Age (years)**                                       53.42±13.60          60.08±11.34            51.42±13.59          \<0.001^[a](#table-fn1-1470320317752955){ref-type="table-fn"}^

  **Male (%)**                                          603 (40.44)          148 (42.90)            455 (39.70)          0.289^[b](#table-fn1-1470320317752955){ref-type="table-fn"}^

  **Smoker (%)**                                        194 (13.01)          37 (10.72)             157 (13.70)          0.150^[b](#table-fn1-1470320317752955){ref-type="table-fn"}^

  **Age at onset (years)**                              47.42±13.95          50.80±13.30            46.40±13.98          \<0.001^[a](#table-fn1-1470320317752955){ref-type="table-fn"}^

  **Duration of diabetes (years)**                      5.50±5.64            8.97±7.13              4.45±4.62            \<0.001^[a](#table-fn1-1470320317752955){ref-type="table-fn"}^

  **BMI (kg/m^2^)**                                     24.78±3.74           24.36±3.30             24.91±3.85           0.009^[a](#table-fn1-1470320317752955){ref-type="table-fn"}^

  **C-peptide**                                         1.74 (1.00--2.84)    1.92 (0.95--2.90)      1.70 (1.02--2.84)    0.737^[a](#table-fn1-1470320317752955){ref-type="table-fn"}^

  **Hypertension (%)**                                  277 (18.60)          107 (31.01)            170 (14.85)          \<0.001^[b](#table-fn1-1470320317752955){ref-type="table-fn"}^

   **SBP (mmHg)**                                       133.55±22.52         145.52±24.76           129.94±20.09         \<0.001^[a](#table-fn1-1470320317752955){ref-type="table-fn"}^

   **DBP (mmHg)**                                       80.15±11.41          82.94±13.34            79.31±10.62          \<0.001^[a](#table-fn1-1470320317752955){ref-type="table-fn"}^

  **HbA~1c~**                                           7.86±1.98            8.70±2.18              7.61±1.84            \<0.001^[a](#table-fn1-1470320317752955){ref-type="table-fn"}^

  **FPG (mmol/l)**                                      8.82±3.53            10.10±4.36             8.43±3.14            \<0.001^[a](#table-fn1-1470320317752955){ref-type="table-fn"}^

  **TG (mmol/l)**                                       1.35 (0.92--2.00)    1.44 (1.01--2.21)      1.30 (0.90--1.95)    0.002^[c](#table-fn1-1470320317752955){ref-type="table-fn"}^

  **TC (mmol/l)**                                       5.49±1.26            5.76±1.35              5.41±1.22            \<0.001^[a](#table-fn1-1470320317752955){ref-type="table-fn"}^

  **LDL-C (mmol/l)**                                    3.40 (2.80--4.00)    3.60 (2.90--4.30)      3.30 (2.70--4.00)    0.982^[a](#table-fn1-1470320317752955){ref-type="table-fn"}^

  **HDL-C (mmol/l)**                                    1.21 (1.02--1.44)    1.18 (0.99--1.43)      1.21 (1.03--1.44)    0.373^[a](#table-fn1-1470320317752955){ref-type="table-fn"}^

  **Plasma urea (mmol/l)**                              5.96±3.15            7.56±4.83              5.47±2.21            \<0.001^[c](#table-fn1-1470320317752955){ref-type="table-fn"}^

  **Plasma creatinine (μmol/l)**                        78.82±44.92          99.61±73.85            72.55±28.55          \<0.001^[c](#table-fn1-1470320317752955){ref-type="table-fn"}^

  **ACR (mg/g)**                                        1.82 (0.88--6.97)    9.02 (1.79--68.58)     1.46 (0.80--3.79)    \<0.001^[c](#table-fn1-1470320317752955){ref-type="table-fn"}^

  **AER (μg/min)**                                      9.35 (5.57--29.57)   50.75 (9.10--383.82)   9.11 (5.48--25.58)   \<0.001^[c](#table-fn1-1470320317752955){ref-type="table-fn"}^

  **Concordance between DR and diabetic nephropathy**                                                                    

  **Diabetes without**\                                 1209                 206 (67.32)            1003 (93.48)         \<0.001^[b](#table-fn1-1470320317752955){ref-type="table-fn"}^
  **nephropathy**                                                                                                        

  **Diabetes with**\                                    170                  100 (32.68)            70 (6.52)            
  **nephropathy**                                                                                                        

  **Total**                                             1379                 306 (100)              1073 (100)           
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Data are shown as means ± SD, median (interquartile range) or *n* (percentage). ^a^Derived from the *t* test. ^b^Derived from the *χ^2^* test. ^c^Derived from the Mann--Whitney *U* test.

DR: diabetic retinopathy; BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; Hb: hemoglobin; FPG: fasting plasma glucose; TG: triglyceride; TC: total cholesterol; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; ACR: albumin-to-creatinine ratio; AER: albumin excretion rate.

Concordance between DR and diabetic nephropathy defined by ACR/AER {#section13-1470320317752955}
------------------------------------------------------------------

Participants were stratified according to normoalbuminuria, microalbuminuria and macroalbuminuria. According to ACR or AER, microalbuminuria and macroalbuminuria were defined as diabetic nephropathy. As shown in [Table 1](#table1-1470320317752955){ref-type="table"}, the DR cases contrasted with DNR patients in having a significantly higher proportion of diabetic nephropathy (χ^2^ = 150.713, *p* \< 0.001), which indicated a strong concordance between DR and diabetic nephropathy.

The relation between *ACE* and *AGT* gene polymorphism and DR {#section14-1470320317752955}
-------------------------------------------------------------

The genotype and allele frequencies of the *ACE* I/D and *AGT* M/T are shown in [Table 2](#table2-1470320317752955){ref-type="table"}. Genotype frequencies in all groups are all in accordance with the Hardy-Weinberg equilibrium (all *p* \> 0.05). Patients with the presence of retinopathy compared to the absence had no significant association with the frequency of *ACE* genotype (DD vs. DI vs. II, χ^2^ = 2.076, *p* = 0.354) and *AGT* genotype (MM vs. MT vs. TT, χ^2^ = 1.656, *p* = 0.437), as well as the frequency of allele (D vs. I, χ^2^ = 0.160, *p* = 0.689; M vs. T, χ^2^ = 1.576, *p* = 0.209) ([Table 2](#table2-1470320317752955){ref-type="table"}).

###### 

Association of RAS polymorphisms with DR in type 2 diabetes.

![](10.1177_1470320317752955-table2)

  ---------------------------------------------------------------------------------------------------------------------------------------------------------
  Genotype\    Total    DNR            DR            Comparison         *p* ^[a](#table-fn3-1470320317752955){ref-type="table-fn"}^   Power value   
  and allele                                                                                                                                        
  ------------ -------- -------------- ------------- ------------------ ------------------------------------------------------------- ------------- -------
  **ACE**      **DD**   166            124 (10.87)   42 (12.21)         DD vs. DI+II                                                  0.489         0.112

  **DI**       645      507 (44.43)    138 (40.12)   DI vs. DD+II       0.157                                                         0.291         

  **II**       674      510 (44.70)    164 (47.67)   II vs. DD+DI       0.331                                                         0.163         

  **Total**    1485     1141 (100)     344 (100)     DD vs. DI vs. II   0.354                                                         --            

  **D**        977      755 (33.09)    222 (32.27)   D vs. I            0.689                                                         0.261         

  **I**        1993     1527 (66.91)   466 (67.73)                                                                                                  

  **Total**    2970     2282 (100)     688 (100)                                                                                                    

  **AGT**      **MM**   30             25 (2.63)     5 (1.71)           MM vs. MT+TT                                                  0.369         0.118

  **MT**       325      254 (26.68)    71 (24.23)    MT vs. MM+TT       0.404                                                         0.128         

  **TT**       890      673 (70.69)    217 (74.06)   TT vs. MM+MT       0.264                                                         0.196         

  **Total**    1245     952 (100)      293 (100)     MM vs. MT vs. TT   0.437                                                         --            

  **M**        385      304 (15.97)    81 (13.82)    M vs. T            0.209                                                         0.234         

  **T**        2105     1600 (84.03)   505 (86.18)                                                                                                  

  **Total**    2490     1904 (100)     586 (100)                                                                                                    
  ---------------------------------------------------------------------------------------------------------------------------------------------------------

Data are shown as *n* (percentage). ^a^Derived from the χ^*2*^ test.

RAS: renin-angiotensin system; DR: diabetic retinopathy; DNR: diabetic non-retinopathy; D: deletion; I: insertion; M: methionine; T: threonine; ACE: angiotensin converting enzyme; AGT: angiotensinogen.

Correction for confounding risk factors {#section15-1470320317752955}
---------------------------------------

To address the confounding risk factors including BMI and hypertension, as displayed in [Table 3](#table3-1470320317752955){ref-type="table"}, obese DR cases had significantly higher frequency of DD genotype (χ^2^ = 4.181, *p* = 0.041). In contrast, patients with normal BMI had similar RAS polymorphisms between the two groups relating to *ACE* genotype and *AGT* genotype (all *p* \> 0.05), as shown in [Table 4](#table4-1470320317752955){ref-type="table"}. No significant difference in the frequency of *ACE* and *AGT* genotypes and alleles relating to DR was displayed in the hypertensive and normotensive patients (all *p* \> 0.05).

###### 

Association of RAS polymorphisms with BMI and DR in type 2 diabetes.

![](10.1177_1470320317752955-table3)

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Genotype\    Patients with BMI-defined obesity   Patients with normal BMI                                                                                                                               
  and allele                                                                                                                                                                                              
  ------------ ----------------------------------- -------------------------- ------------- ------------------ -------------- ------------- ------------- ------------- ------------------ -------------- -------
  **ACE**      **DD**                              69                         48 (9.50)     21 (15.67)         DD vs. DI+II   0.041         96            75 (11.90)    21 (10.10)         DD vs. DI+II   0.478

  **DI**       278                                 226 (44.75)                52 (38.81)    DI vs. DD+II       0.217          364           279 (44.29)   85 (40.87)    DI vs. DD+II       0.388          

  **II**       292                                 231 (45.74)                61 (45.52)    II vs. DD+DI       0.964          378           276 (43.81)   102 (49.04)   II vs. DD+DI       0.189          

  **Total**    639                                 505 (100)                  134 (100)     DD vs. DI VS. II   0.101          838           630 (100)     208 (100)     DD vs. DI vs. II   0.403          

  **D**        416                                 322 (31.88)                94 (35.07)    D vs. I            0.321          556           429 (34.05)   127 (30.53)   D vs. I            0.310          

  **I**        862                                 688 (68.12)                174 (64.93)   1120               831 (65.95)    289 (69.47)                                                                 

  **Total**    1,278                               1010 (100)                 268 (100)     1676               1260 (100)     416 (100)                                                                   

  **AGT**      **MM**                              16                         14 (3.38)     2 (1.80)           MM vs. MT+TT   0.390         14            11 (2.07)     3 (1.67)           MM vs. MT+TT   0.738

  **MT**       133                                 107 (25.85)                26 (23.42)    MT vs. MM+TT       0.602          189           145 (27.26)   44 (24.44)    MT vs. MM+TT       0.460          

  **TT**       376                                 293 (70.77)                83 (74.77)    TT vs. MM+MT       0.406          509           376 (70.68)   133 (73.89)   TT vs. MM+MT       0.409          

  **Total**    525                                 414 (100)                  111 (100)     MM vs. MT vs. TT   0.573          712           532 (100)     180 (100)     MM vs. MT vs. TT   0.703          

  **M**        165                                 135 (16.30)                30 (13.51)    M vs. T            0.310          217           167 (15.70)   50 (13.89)    M vs. T            0.410          

  **T**        885                                 693 (83.70)                192 (86.49)   1207               897 (84.30)    310 (86.11)                                                                 

  **Total**    1050                                828 (100)                  222 (100)     1424               1064 (100)     360 (100)                                                                   
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Data are shown as *n* (percentage). ^a^Derived from the χ^2^ test. Obesity was defined as BMI value ≥ 25 kg/m^2^ and normal BMI was defined as 18.5 kg/m^2^ ≤ BMI \< 23 kg/m^2^.

RAS: renin-angiotensin system; BMI: body mass index; DR: diabetic retinopathy; DNR: diabetic non-retinopathy; D: deletion; I: insertion; M: methionine; T: threonine; ACE: angiotensin converting enzyme; AGT: angiotensinogen.

###### 

Association of RAS polymorphisms with hypertension and DR in patients with type 2 diabetes.

![](10.1177_1470320317752955-table4)

  Genotype and allele   Hypertensive patients with type 2 diabetes   Normotensive patients with type 2 diabetes                                                                                                                               
  --------------------- -------------------------------------------- -------------------------------------------- ------------- ------------------ -------------- ------------- ------------- ------------- ------------------ -------------- -------
  **ACE**               **DD**                                       29                                           20 (11.76)    9 (8.41)           DD vs. DI+II   0.375         137           104 (10.72)   33 (13.92)         DD vs. DI+II   0.164
  **DI**                115                                          68 (40.00)                                   47 (43.93)    DI vs. DD+II       0.519          530           439 (45.26)   91 (38.40)    DI vs. DD+II       0.056          
  **II**                133                                          82 (48.24)                                   51 (47.66)    II vs. DD+DI       0.926          540           427 (44.02)   113 (47.68)   II vs. DD+DI       0.310          
  **Total**             277                                          170 (100)                                    107 (100)     DD vs. DI vs. II   0.621          1207          970 (100)     237 (100)     DD vs. DI VS. II   0.115          
  **D**                 173                                          108 (31.76)                                  65 (30.37)    D vs. I            0.731          804           647 (33.35)   157 (33.12)   D vs. I            0.925          
  **I**                 381                                          232 (68.24)                                  149 (69.63)   1610               1293 (66.65)   317 (66.88)                                                                 
  **Total**             554                                          340 (100)                                    214 (100)     2414               1940 (100)     474 (100)                                                                   
  **AGT**               **MM**                                       4                                            2 (1.49)      2 (2.27)           MM vs. MT+TT   0.669         26            23 (2.82)     3 (1.46)           MM vs. MT+TT   0.272
  **MT**                57                                           33 (24.63)                                   24 (27.27)    MT vs. MM+TT       0.659          268           221 (27.05)   47 (22.93)    MT vs. MM+TT       0.230          
  **TT**                161                                          99 (73.88)                                   62 (70.45)    TT vs. MM+MT       0.576          728           573 (70.13)   155 (75.61)   TT vs. MM+MT       0.122          
  **Total**             222                                          134 (100)                                    88 (100)      MM vs. MT vs. TT   0.815          1022          817 (100)     205 (100)     MM vs. MT vs. TT   0.231          
  **M**                 65                                           37 (13.81)                                   28 (15.91)    M vs. T            0.540          320           267 (16.34)   53 (12.93)    M vs. T            0.089          
  **T**                 379                                          231 (86.19)                                  148 (84.09)   1724               1367 (83.66)   357 (87.07)                                                                 
  **Total**             444                                          268 (100)                                    176 (100)     2044               1634 (100)     410 (100)                                                                   

Data are shown as *n* (percentage). ^a^Derived from the χ^2^ test.

RAS: renin-angiotensin system; DR: diabetic retinopathy; DNR: diabetic non-retinopathy; D: deletion; I: insertion; M: methionine; T: threonine; ACE: angiotensin-converting enzyme; AGT: angiotensinogen.

In binary logistic regression with groups (DNR vs. DR) as the dependent variable and age, age of onset, duration of diabetes, BMI, hypertension (%), HbA~1c~, FPG, TG, TC, LDL-C, HDL-C, plasma urea, plasma creatinine, ACR, AER, and *ACE/AGT* genotype as covariates, the association of the *ACE* and *AGT* gene polymorphisms with DR in T2DM patients still was not significant after adjusting for confounding factors ([Table 5](#table5-1470320317752955){ref-type="table"}). Otherwise, no significant association was found between *ACE* and *AGT* gene polymorphisms and DR in all the stratified BMI and hypertension analyses after adjustment for covariates (all *p* \> 0.05). The power value showed that the negative findings were partly due to lack of study power displayed in [Table 2](#table2-1470320317752955){ref-type="table"} and also displayed low value in other stratified BMI and hypertension analyses (data not shown).

###### 

ORs of ACE/AGT genotypes for diabetic retinopathy in Chinese patients with type 2 diabetes.

![](10.1177_1470320317752955-table5)

                                  Model 1               Model 2                Model 3                Model 4                                                                                     
  --------- --------------------- --------------------- ---------------------- ---------------------- ---------------------- ---------------------- ---------------------- ---------------------- -------
  **ACE**   **DD**                0.974 (0.610-1.557)   0.914                  0.999 (0.621--1.609)   0.998                  0.968 (0.594--1.577)   0.897                  0.649 (0.160--2.633)   0.545
  **DI**    0.842 (0.620-1.143)   0.269                 0.839 (0.614--1.147)   0.271                  0.821 (0.596--1.132)   0.230                  0.986 (0.481--2.020)   0.970                  
  **II**    1                     --                    1                      --                     1                      --                     1                      --                     
  **AGT**   **MM**                0.633 (0.224-1.794)   0.390                  0.632 (0.210--1.903)   0.415                  0.648 (0.209--2.007)   0.452                  0                      0.998
  **MT**    0.837 (0.600-1.166)   0.292                 0.837 (0.597--1.173)   0.301                  0.809 (0.574--1.142)   0.228                  1.220 (0.576--2.584)   0.604                  
  **TT**    1                     --                    1                      --                     1                      --                     1                      --                     

Model 1 adjusted for age, sex, age onset, duration of diabetes. Model 2 adjusted for model 1 + BMI, hypertension. Model 3 adjusted for model 2 + HbA1c, FPG, TG and TC. Model 4 adjusted for model 3 + plasma urea, plasma creatinine, ACR and AER.

ORs: odds ratios; ACE: angiotensin-converting enzyme; AGT: angiotensinogen; D: deletion; I: insertion; M: methionine; T: threonine; BMI: body mass index; Hb: hemoglobin; CI: confidence interval; FPG: fasting plasma glucose; TG: triglyceride; TC: total cholesterol; AER: albumin excretion rate.

Discussion {#section16-1470320317752955}
==========

In some population studies, the variants of the RAS gene have been associated with diabetes and its complications, and inhibition of RAS has prevented the risk of diabetes and its complications.^[@bibr11-1470320317752955]^ Most studies that evaluated the role of *ACE* gene polymorphism with DR have different claims, yet few studies that assessed the *AGT* gene polymorphism in T2DM patients with retinopathy displayed no significant association.^[@bibr6-1470320317752955],[@bibr11-1470320317752955]^

In this study, we analyzed the relationship between *ACE* and *AGT* gene polymorphism and T2DM patients with retinopathy. In a total of 1491 T2DM patients, we found that no significant difference existed between DR and DNR patients regarding *ACE* or *AGT* genotype or allele, and our negative findings are consistent with previous studies.^[@bibr1-1470320317752955],[@bibr11-1470320317752955],[@bibr28-1470320317752955]^ These findings indicate that the suggested role of genetics in predisposition to DR is unlikely to be mediated through differences in the DNA sequence of the *ACE* or *AGT* gene, and that the I/D and M/T polymorphisms of this gene are not a useful marker to assess susceptibility to DR. Otherwise, some discrepancy existed in studies by other researchers. Cheema et al.^[@bibr18-1470320317752955]^ investigated the association and interaction between RAS gene polymorphisms and the development and progression of DR, which indicated RAS polymorphism was a significant risk factor both for nonproliferative DR and proliferative DR. Moreover, Nikzamir and co-authors^[@bibr29-1470320317752955]^ have found that the D allele of the *ACE* gene is independently associated with retinopathy in Iranian T2DM patients. Hernández et al.^[@bibr30-1470320317752955]^ reported the *ACE* I/D polymorphism was observed to be significantly associated with nonproliferative DR, but not with proliferative DR in a Pakistani population. Globocnik-Petrovic and colleagues^[@bibr1-1470320317752955]^ thought that the *ACE* I/D gene polymorphism did not contribute to the genetic susceptibility to nonproliferative, proliferative or severe proliferative DR in a group of Caucasian T2DM individuals. We estimate that the possible reason for this discrepancy in these results may be related to ethnic differences and lifestyle factors. A meta-analysis of larger numbers of patients regarding *ACE* I/D polymorphism on risk of DR was performed and found that *ACE* I/D gene polymorphism might contribute to DR development, especially in the Asian T2DM group.^[@bibr31-1470320317752955]^ We speculate that the high heterogeneity in these results may lead to different outcomes in this study. Another meta-analysis was conducted to assess the relationship between the pattern of *ACE* gene polymorphism and T2DM patients' presence or absence of retinopathy and found that the frequency of the DD genotype was not significantly different between the groups.^[@bibr32-1470320317752955]^ Abhary et al. also conducted a meta-analysis and found no significant association between *ACE* polymorphisms and DR.^[@bibr33-1470320317752955]^ The finding was consistent with our observations in this study.

In our study, we further assessed the *ACE* and *AGT* gene polymorphism with DR relating to obese and hypertensive patients. We have found that patients with normal BMI had similar RAS polymorphisms between the two groups relating to *ACE* genotype and *AGT* genotype, but in obese individuals, DR cases had a significantly higher frequency of DD genotype. Previous work reported that significant differences in FPG,^[@bibr34-1470320317752955]^ DM duration,^[@bibr29-1470320317752955]^ age, BMI, SBP, DBP^[@bibr6-1470320317752955]^ and ACE activity^[@bibr29-1470320317752955],[@bibr34-1470320317752955]^ existed between the DNR and DR groups. T2DM coexists with immunological disturbances^[@bibr35-1470320317752955][@bibr36-1470320317752955]--[@bibr37-1470320317752955]^ and could lead to retinopathy.^[@bibr38-1470320317752955],[@bibr39-1470320317752955]^ Therefore, clinical characteristics of T2DM patients such as obesity may interact with genetic factors for the development of retinopathy, as highlighted in a previous report.^[@bibr12-1470320317752955]^ However, Pan et al.^[@bibr40-1470320317752955]^ found that frequencies of the *ACE* genotypes (DD, ID and II) were not significant among the BMI-defined groups of Chinese patients with T2DM. In our study, regarding the outcome of binary logistic regression on the stratified BMI analyses after adjustment for covariates, no significant association between *ACE* and *AGT* gene polymorphisms and the risk of retinopathy in diabetes patients was found in all the comparisons, and the possible reasons were due to the small sample or others. Therefore, more attention should be paid to whether the *ACE* and *AGT* gene polymorphisms with the interaction of BMI facilitated the development of diabetes to DR.

Moreover, this study disclosed that no significant difference was displayed with respect to the frequency of *ACE* and *AGT* genotypes and alleles relating to the risk of DR in hypertensive and normotensive T2DM patients, suggesting that potential interactions of the RAS gene polymorphisms with blood pressure did not promote the pathogenesis of DR. Thomas et al.^[@bibr12-1470320317752955]^ found no significant relationship was identified between these polymorphisms and blood pressure in a Chinese population relating to *ACE* and *AGT* genotypes. Zarouk and colleagues^[@bibr41-1470320317752955]^ found that the DD genotype and the D allele of the *ACE* gene were associated with hypertension and T2DM in Egyptian patients. Ramachandran et al.^[@bibr42-1470320317752955]^ discovered that the D allele of the *ACE* gene was associated with essential hypertension and T2DM in Malaysian individuals. Nakhjavani et al.^[@bibr43-1470320317752955]^ concluded that the DD polymorphism in the *ACE* gene was independently associated with hypertension in Iranian type 2 diabetic patients. Xue and colleagues^[@bibr44-1470320317752955]^ showed that the M allele of the *AGT* gene was probably related to hypertension in Chinese female T2DM patients. Zhou et al.^[@bibr45-1470320317752955]^ predicted that *ACE* gene deletion is a risk factor for hypertension but is not a risk factor for diabetes in an elderly population. RAS is clearly involved in the maintenance of blood pressure^[@bibr46-1470320317752955]^ and a significant relationship exists between blood pressure and retinopathy.^[@bibr47-1470320317752955]^ Taken together, no significant difference in the *ACE/AGT* polymorphisms existed after adjusting for hypertension. The possible reasons may be due to the different ethnic groups, the diabetic control group with potential complications, small sample size or lower power value in some comparisons.

Some limitations should be noticed when interpreting our findings. Firstly, because of lack sufficient data, we were unable to perform further analysis of the relationship between RAS gene polymorphism and DR according to glycemic index, TG, HbA~1c~, duration of DM and so on. Secondly, the *ACE2, AT1R* and *AT2R* gene polymorphisms of the RAS system not further analyzed might play an important role in the relationship, which may influence our findings. Otherwise, the lower power values may also have influenced the findings. Even so, we hope that our findings may provide a line of evidence for further studies.

Conclusions {#section17-1470320317752955}
===========

In summary, the results in this study indicate no significant association between *ACE/AGT* gene polymorphisms and DR in Chinese patients with T2DM; however, more investigations are needed to further prove our findings.
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